Elizabeth Thompson
Family · Williston, FLNPI 1720313950
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Novo Nordisk at 30.2% of the total.
Across 219 payments — averaging $13.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$924
- AbbVie$644
- Optinose US, Inc.$284
- Amgen$233
- Lilly USA, LLC$116
- Pfizer$108
- plus $748 from 18 others
What the payments were for
- Food & beverage$3,058100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 68 | $924 |
| AbbVie | 69 | $644 |
| Optinose US, Inc. | 13 | $284 |
| Amgen(2 entities) | 15 | $233 |
| Lilly USA, LLC | 7 | $116 |
| Pfizer | 6 | $108 |
| AstraZeneca | 5 | $91 |
| Johnson & Johnson | 4 | $90 |
| IBSA Pharma Inc. | 5 | $83 |
| Amarin Pharma, Inc. | 4 | $78 |
| Exact Sciences | 3 | $53 |
| Jazz Pharmaceuticals Inc. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Acella Pharmaceuticals, LLC | 2 | $34 |
| GSK | 2 | $29 |
| Tolmar, Inc. | 2 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Kaleo, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Clarus Therapeutics Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Abbott | 1 | $16 |
How this compares
$3,058 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 46 | $48,550 |
| OzempicSemaglutide | 29 | $43,531 |
| RybelsusSemaglutide | 12 | $24,015 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $16,409 |
| JanuviaSitagliptin Phosphate | 15 | $12,640 |
| EliquisApixaban | 11 | $11,531 |
| LyricaPregabalin | 11 | $6,692 |
| Levothyroxine Sodium | 229 | $3,030 |
| Rosuvastatin Calcium | 216 | $2,928 |
| SynthroidLevothyroxine Sodium | 29 | $2,883 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $1,932 |
| Atorvastatin Calcium | 194 | $1,876 |
| Lisinopril | 199 | $1,535 |
| Losartan Potassium | 150 | $1,263 |
| Omeprazole | 85 | $1,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $924 | $67,54641 claims |
| Lilly USA, LLCMounjaro | $116 | $48,55046 claims |
| PfizerEliquis, Lyrica | $108 | $18,22322 claims |
| AbbVieSynthroid | $644 | $2,88329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Williston
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.